#USA #Henderson #VolitionRx #Capture-Seq #Early-Cancer-Detection

Overview of Volition's Breakthrough in Cancer Detection

VolitionRx Limited, a pioneering multi-national epigenetics company, has made significant strides in the early detection of cancer utilizing its innovative Capture-Seq™ technology. This development was highlighted in their recent announcement, emphasizing an impressive sensitivity rate of over 95% in detecting early-stage cancers within a blinded validation cohort. The implications of this technology could revolutionize cancer diagnostics and management worldwide.

Detailed Findings from the Study

In a blinded validation study involving 81 subjects—comprised of patients with colorectal and lung cancer (59 participants) and healthy controls (22 participants)—Capture-Seq™ demonstrated remarkable efficacy in identifying cancers at stages I and II. The results indicate:

• - Stage I Sensitivity: 94% (17 of 18 cases correctly identified)
• - Stage II Sensitivity: 96% (26 of 27 cases)
• - Stage III Sensitivity: 100% (2 of 2 cases)
• - Stage IV Sensitivity: 91% (10 of 11 cases)
• - Controls Specificity: 95% (21 of 22 healthy individuals)

These statistics highlight not only the effectiveness of Volition's technology in detecting early-stage cancers but also its potential reliability when utilized in practical settings.

Understanding Capture-Seq™ Technology

Dr. Jake Micallef, Chief Scientific Officer at Volition, elaborated on how their liquid biopsy method captures and purifies tumor DNA from plasma samples.

The Capture-Seq™ process ensures that the resulting circulating tumor DNA (ctDNA) samples for analysis are nearly pure, positively impacting the sensitivity of cancer detection.

• - The Capture-Seq™ technology focuses on circulating cell-free nucleoproteins, a novel approach that has not been extensively explored in the field of liquid biopsies so far.
• - It employs an innovative two-step process: physical enrichment of plasma samples and subsequent bioinformatic analysis that removes most non-tumor cfDNA sequences, yielding over 99% purity in ctDNA datasets.

This pioneering method is expected to bring forth novel biomarkers for liquid biopsy, presenting vast possibilities for early cancer detection and possibly impacting diagnostics in veterinary medicine as well.

Potential Market Impact and Future Directions

The global market opportunity with the Capture-Seq™ technology is substantial, with estimates suggesting it could tap into a total addressable market approaching $23 billion annually for multi-cancer early detection (MCED) and more than $13 billion for minimal residual disease (MRD) detection.

• - Mr. Gael Forterre, Volition's Chief Commercial Officer, noted the keen interest from potential licensing partners, indicating a growing excitement about this technology’s applications in both human and veterinary markets.
• - The company is in active discussions with several leading diagnostic companies to expedite the development and commercialization of Capture-Seq™.

Conclusion

VolitionRx is at the forefront of changing cancer diagnostics through Capture-Seq™, offering hope for earlier detection that could lead to better outcomes for cancer patients. With ongoing validation and potential clinical adoption, this breakthrough technology might soon fulfill a pressing need in cancer detection services and fundamentally alter early cancer management practices across healthcare systems globally.